| Autor: |
Sbrana, Francesco, Pianelli, Mascia, Luciani, Roberta, Bigazzi, Federico, Corciulo, Carmen, Ripoli, Andrea, Sampietro, Tiziana, Dal Pino, Beatrice |
| Předmět: |
|
| Zdroj: |
Journal of Clinical Apheresis; Feb2024, Vol. 39 Issue 1, p1-5, 5p |
| Abstrakt: |
Background: Despite advance in pharmacotherapy of lipid disorders, lipoprotein apheresis (LA) plays a leading role in the management of severe hypercholesterolemia and in atherosclerosis prevention. Methods: Aim of this study was to retrospectively evaluate Charlson Comorbidity Index (CCI), presence of major comorbidity, and/or concomitant polypharmacy (definite as 5+ drugs daily) in patients with inherited dyslipidemias on chronic LA. Results: Since 1994, we performed more than 500 LA treatment/year and followed a total of 83 patients (age 56 [47–65] years, male 75%). In subjects with more than 5 years of LA treatment (38 patients, age 54 [45–62] years, male 66%), at the end of the observation time (9 [7–16] years), patients had higher CCI, polypharmacy, anemia, heart failure, peptic ulcer disease, and benign prostatic hyperplasia. Discussion: Even in the era of new lipid‐lowering therapies, the LA treatment established itself as a safe and lifesaving intervention. Patients on chronic LA require a multidisciplinary approach to address their comorbidity and the apheresis unit's medical staff (doctors and nurses) play a pivotal role creating a bridge toward the general practitioner and other specialists for overcoming clinical issues. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text